Home Authors Posts by Namitha Thambi

Namitha Thambi

Namitha Thambi
63 POSTS 0 COMMENTS
Hydroxychloroquine Clinical Trials Resume
News

COVID-19: Clinical Trials Of Hydroxychloroquine Resumes

Namitha Thambi - 0
Glenmark's Cholesterol lowering drugs
News

Glenmark Pharma’s Cholesterol Lowering Drugs Get USFDA Approval

Namitha Thambi - 0
Remdesivir price in India
News

Cipla To Price Remdesivir For COVID-19 Under Rs 5,000

Namitha Thambi - 0
Both the World Health Organization (WHO) and NIH’s National Heart, Lung, and Blood Institute (NHLBI) have halted hydroxychloroquine's clinical studies conducted to assess the safety and effectiveness of the drug to treat adults with Covid-19 and Novartis, due to its inability to recruit enough patients, ended the Phase III trials of the same drug. One week before, the FDA had revoked its emergency use authorization (EUA) for hydroxychloroquine due to a randomized controlled clinical trial that showed no clinical benefit and the lack of consistent replication of earlier promising results. A data and safety monitoring board (DSMB) found that hydroxychloroquine is not beneficial in treating COVID-19, compared to placebo. However, NIH noted that the drug is not harmful. DSMB recommended the National Heart, Lung, and Blood Institute (NHLBI) to halt the study after a fourth interim analysis.  The randomized, blinded, placebo-controlled clinical trial was conducted in more than 500 patients infected with the novel coronavirus, among which 470 were recruited at the time of trial’s closure. 400mg hydroxychloroquine was given twice a day to the participants for two doses, followed by 200mg twice daily for the next eight doses, or a placebo twice daily for five days. Meanwhile, Novartis, a Swiss pharmaceutical company suspended the phase III clinical trials of hydroxychloroquine, as the completion of the trial was infeasible due to enrollment challenges. No conclusions have been made on the efficacy of the drug in treating COVID-19 and no safety issues have been reported, the company noted. Due to the recruitment challenges, the clinical team was unable to collect meaningful data in a reasonable timeframe to determine the effectiveness of HCQ in treating patients with Covid-19, said Novartis. However, Novartis will continue to supply HCQ upon government requests and for certain ongoing investigator-initiated trials (IITs). Since HCQ showed no benefit compared to standard of care in reducing deaths, the World Health Organization also halted the clinical trials of hydroxychloroquine on June 17. Source
News

NIH, WHO And Novartis Ended Hydroxychloroquine Trials For COVID-19

Namitha Thambi - 0
India Import 80% APIs From China 
News

India China Conflicts To Affect 80% Pharma Raw Material Supply

Namitha Thambi - 0
Reviving Pharma Ancillary Industry
News

The Indian Pharma Ancillary Industry Needs To Be Saved Immediately :...

Namitha Thambi - 0
Phase-3 Trials Of Favipiravir By Glenmark
News

Glenmark Initiates Phase-3 Clinical Trials For Favipiravir To Treat COVID-19

Namitha Thambi - 0
COVID-19 Testing Kits 'Made In Andhra Pradesh' Launched
News

COVID-19 Testing Kits ‘Made In Andhra Pradesh’ Launched

Namitha Thambi - 0
BCPL to manufacture Hydroxychloroquine
News

India’s First Pharma Company – BCPL Gets Approval To Manufacture Hydroxychloroquine

Namitha Thambi - 0
US Request India For Hydroxychloroquine
News

US Requests India To Reconsider It’s Hold On The Release Of...

Namitha Thambi - 0
Pink Eye A Symptom Of COVID-19
News

Coronavirus Can Spread Via Tears – Pink Eye Could Be A...

Namitha Thambi - 0
Hydroxychloroquine Buying Restrictions in India
News

Drug Shortage: Hydroxychloroquine Is Now A Schedule H1 Drug

Namitha Thambi - 0
Short film to salute medical professionals
News

Mankind Pharma’s Campaign Salutes Selfless Medical Professionals Helping Fight COVID-19

Namitha Thambi - 0
new thin and porous carbon membrane
News

One Molecule Thick Membrane To Generate 100 Times More Power

Namitha Thambi - 0
basic electronic structure of benzene
News

Mystery Of Benzene Electronic Structure Decoded After 90 Years

Namitha Thambi - 0
error free dynamic catalysts
News

Scientists Develop Error-Free Dynamic Catalysts To Avoid Side Reactions

Namitha Thambi - 0
Thermo Fisher To Acquire QIAGEN
News

Thermo Fisher To Acquire QIAGEN For $11.5 Billion

Namitha Thambi - 0
drug shortage due to coronavirus
News

Sun Pharma Warns Shortage In Hypertension Drugs Due To Coronavirus Outbreak

Namitha Thambi - 0
ienaics approach in separation chemistry
News

Researchers Develop New Approach Towards Greener Recycling Of Metals

Namitha Thambi - 0
Synthesizing superatoms to Substitute elements
News

Superatoms Synthesized By Scientists Could Replace Elements

Namitha Thambi - 0
synthesis of planar chiral macrocycles
News

Biocatalysts Can Simplify Synthesis Of Planar Chiral Macrocycles

Namitha Thambi - 0
simpler method for Suzuki-Miyaura reaction
News

Scientists Develop An Easy Way For Synthesizing Organic Compounds

Namitha Thambi - 0
new compound with strong antidiabetic properties
News

RUDN Chemists Develop A Strong Anti-Diabetic Compound

Namitha Thambi - 0
safer hydrogenation process
News

A Safer Hydrogenation Process That Doesn’t Need Compressed Hydrogen Cylinders

Namitha Thambi - 0
mechanism behind Grignard reaction
News

The Mechanism Behind 120 Year Old Grignard Reaction Finally Uncovered

Namitha Thambi - 0
123Page 2 of 3
- Advertisement -

MOST POPULAR

HOT NEWS